drugset / Trial / NCT06972641
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, multicenter, open-label umbrella clinical study planned to enroll 126 subjects with acute myeloid leukemia/myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation. Subjects eligible for enrollment were grouped based on the results of the initial myeloid genomic second-generation sequencing, and were given different regimens of maintenance therapy, with the aim of evaluating the efficacy and safety of the maintenance regimen.
Timeline
- Start
- 2025-06-10
- Primary completion
- 2030-03-31
- Completion
- 2030-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avastinib | Unknown | 100 mg | — |
| Subject | Decitabine | Small molecule | 3.5 mg/m2 | — |
| Subject | Selenisol | Unknown | 20 mg | Oral |
| Subject | Sorafenib | Small molecule | 0.2 g | Oral |
| Subject | Venetoclax | Small molecule | 50 mg | Oral |
| Subject | Venetoclax | Small molecule | 100 mg | Oral |
| Subject | giritinib | Unknown | 40 mg | Oral |